Viewing data from:

PROCHLORPERAZINE EDISYLATE

ANDA

PROCHLORPERAZINE EDISYLATE | A040505 | TEVA PARENTERAL MEDICINES INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Prochlorperazine Edisylate (2023)

Total Spending

$124K

Total Claims

979

Beneficiaries

229

Avg Cost/Unit

$3.56

Spending Trend

$212K(2019)→$254K(2020)→$196K(2021)→$164K(2022)→$124K(2023)

YoY Change:-32.5%

5yr CAGR:-18.6%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain4 active DMFs4 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

TRIFARMA SPAPROCHLORPERAZINE EDISYLATE USP

DMF 160552002

EMCURE PHARMACEUTICALS LTDPROCHLORPERAZINE EDISYLATE USP

DMF 311762016

BIOPHORE INDIA PHARMACEUTICALS PVT LTDPROCHLORPERAZINE EDISYLATE

DMF 321782017

RAKS PHARMA PVT LTDPROCHLORPERAZINE EDISYLATE USP

DMF 336932019

SANOFI INCInactivePROCHLORPERAZINE EDISYLATE

DMF 35451979

NV ORGANONInactivePROCHLORPERAZINE EDISYLATE

DMF 54251984

AMERICAN CHEMICAL INDUSTRIAL CORPInactivePROCHLORPERAZINE EDISYLATE USP XXI

DMF 59411985

JOHNSON MATTHEY INCInactivePROCHLORPERAZINE EDISYLATE

DMF 102131993

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — EQ 5MG BASE/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: May 30, 2003

No patent or exclusivity listings for this strength.